Literature DB >> 28573377

The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial.

F D Wolinsky1,2,3, Y Lou4, S W Edmonds5,6,7, K G Saag8, D W Roblin9,10, N C Wright8,11, M P Jones4, P Cram5,12,13.   

Abstract

Patients may exhibit risky bone health behaviors. In a large pragmatic clinical trial, we tested whether a tailored patient activation DXA result letter accompanied by a bone health brochure led to smoking and excessive drinking cessations. The intervention did not, however, alter these risky bone health behaviors.
INTRODUCTION: Besides dual-energy x-ray absorptiometry (DXA) screening and pharmacotherapy when indicated, beneficial bone health behaviors including proper calcium and vitamin D intake and weight-bearing and muscle-strengthening exercise should be encouraged. Similarly, risky bone health behaviors like smoking and excessive drinking should be discouraged. We examined whether a direct-to-patient activation intervention led to smoking and excessive drinking cessations.
METHODS: The Patient Activation after DXA Result Notification (PAADRN) pragmatic clinical trial enrolled 7749 patients between February 2012 and August 2014. Interviews occurred at baseline and 12 and 52 weeks later. Intervention subjects were mailed an individually tailored DXA results letter accompanied by a bone health educational brochure 4 weeks post-DXA. Usual care subjects were not sent these materials. Smoking and excessive drinking were assessed by self-report at each interview. Intention-to-treat linear probability models were used.
RESULTS: Mean age was 66.6 years, 83.8% were women, and 75.3% were Non-Hispanic-Whites. Smoking was reported at baseline by 7.6% of the intervention group vs. 7.7% of the usual care group (p = 0.873). Excessive drinking was reported at baseline by 6.5% of the intervention group vs. 6.5% of the usual care group (p = 0.968). Intention-to-treat analyses indicated no significant differences between the intervention vs. usual care groups at either 12 or 52 weeks post-DXA (all p values ≥ 0.346).
CONCLUSION: An individually tailored DXA result letter accompanied by an educational brochure did not lead to smoking or excessive drinking cessations in patients who received DXA. TRIAL REGISTRATION: clinicaltrials.gov identifier NCT01507662.

Entities:  

Keywords:  Clinical trials; DXA; Drinking; Osteoporosis; Smoking

Mesh:

Year:  2017        PMID: 28573377      PMCID: PMC5670005          DOI: 10.1007/s00198-017-4101-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Measuring physical activity with the behavioral risk factor surveillance system.

Authors:  R C Brownson; D A Jones; M Pratt; C Blanton; G W Heath
Journal:  Med Sci Sports Exerc       Date:  2000-11       Impact factor: 5.411

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Self-efficacy: toward a unifying theory of behavioral change.

Authors:  A Bandura
Journal:  Psychol Rev       Date:  1977-03       Impact factor: 8.934

4.  Current Cigarette Smoking Among Adults - United States, 2005-2015.

Authors:  Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-11       Impact factor: 17.586

5.  Vital signs: binge drinking prevalence, frequency, and intensity among adults - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-13       Impact factor: 17.586

6.  Disparities in osteoporosis treatments.

Authors:  Z Liu; J Weaver; A de Papp; Z Li; J Martin; K Allen; S Hui; E A Imel
Journal:  Osteoporos Int       Date:  2015-07-28       Impact factor: 4.507

7.  The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States.

Authors:  J R Curtis; A Laster; D J Becker; L Carbone; L C Gary; M L Kilgore; R S Matthews; M A Morrisey; K G Saag; S B Tanner; E Delzell
Journal:  Osteoporos Int       Date:  2008-12-24       Impact factor: 4.507

8.  The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health.

Authors:  Stephanie W Edmonds; Fredric D Wolinsky; Alan J Christensen; Xin Lu; Michael P Jones; Douglas W Roblin; Kenneth G Saag; Peter Cram
Journal:  Contemp Clin Trials       Date:  2012-10-17       Impact factor: 2.226

9.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

10.  Developing a bone mineral density test result letter to send to patients: a mixed-methods study.

Authors:  Stephanie W Edmonds; Samantha L Solimeo; Xin Lu; Douglas W Roblin; Kenneth G Saag; Peter Cram
Journal:  Patient Prefer Adherence       Date:  2014-06-05       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.